Bcr‐Abl activates AURKA and AURKB in chronic myeloid leukemia cells <i>via</i> AKT signaling
Jing Yang(Xuzhou Medical College), Akihito Yokoyama(Hiroshima University)
Cited by 39
Related Papers
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
|The Lancet Respiratory Medicine|2016|465
PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
|Molecules|2023|88